

**AKZO NOBEL**

FAX RECEIVED

MAY 23 2001

GROUP 1600

**TELEFAX TRANSMITTAL SHEET**

DATE:

5/22/2001

NO. OF PAGES:

6

(INCLUDING COVER SHEET)

**TO:**

M. Pak

**COMPANY/DEPT.:**

Att#1646

**FAX NO.:**

703.308.4242

**FROM:**

M.G. Sullivan

**COMPANY/DEPT.:**PATENT DEPARTMENT  
ROCKVILLE, MARYLAND**FAX NO.:**

(301) 948-9751

**PHONE NO.:**

(301) 948-7400

**SUBJECT/REFERENCE:**

Dresselmann et al. USSN 08/026,361

**CONFIDENTIAL****REMARKS:**

Pls. accept the following:

- Supplemental Amendment (pgs. 4)
- Version w/ Markings (p. 1)

Thank you.

WARNING: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS ATTORNEY PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS WRONGFUL AND MAY SUBJECT YOU TO CIVIL LIABILITY. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AT: (301) 948-7400, AND RETURN THE ORIGINAL MESSAGE TO US AT: 1300 PICCARD DRIVE, SUITE 206, ROCKVILLE, MARYLAND 20850 VIA THE U.S. POSTAL SERVICE. THANK YOU.

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY: [Signature]Date: 5/22/2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FAX RECEIVED

In re the application of:

MOSSELMAN ET AL.

MAY 23 2001

Serial Number: 08/826,361

Group Art Unit: 1646 GROUP 1600

Filed: March 26, 1997

Examiner: M. Pak

For: NOVEL ESTROGEN RECEPTOR

SUPPLEMENTAL AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

May 22, 2001

Sir:

In further response to the Office Action dated November 22, 2000, please enter the following replacement amendments and reconsider the pending rejections in view of the remarks below.

IN THE CLAIMS:

Please replace claim 1 with the following:

1. (Three times amended) An isolated DNA encoding a human estrogen receptor protein having a DNA-binding domain and a ligand-binding domain, wherein the amino acid sequence of said DNA-binding domain exhibits at least 80% homology with the amino acid sequence shown in SEQ ID NO:3, and the amino acid sequence of said ligand-binding domain exhibits at least 70% homology with

the amino acid sequence shown in SEQ ID NO:4, and wherein said DNA-binding domain targets the receptor protein to a selected hormone responsive element of a target gene and said ligand-binding domain recognizes and binds to an estrogen, thereby modulating expression of said target gene.